Diverse functions of matrix metalloproteinases during fibrosis

DMM Disease Models and Mechanisms

Volumn 7, Issue 2, 2014, Pages 193-203

  Giannandrea, Matthew ^a   Parks, William C ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Collagen; Extracellular matrix; Fibrosis; Metalloproteinase; TIMP

Indexed keywords

MATRIX METALLOPROTEINASE;

ANIMAL; ANTIBODY SPECIFICITY; ENZYMOLOGY; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; MATRIX METALLOPROTEINASES; ORGAN SPECIFICITY;

EID: 84894363753     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.012062     Document Type: Review

References (117)

1. Abraham, A. P., Ma, F. Y., Mulley, W. R., Ozols, E. and Nikolic-Paterson, D. J. (2012). Macrophage infiltration and renal damage are independent of matrix metalloproteinase 12 in the obstructed kidney. Nephrology (Carlton) 17, 322-329.
2. Aimes, R. T. and Quigley, J. P. (1995). Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J. Biol. Chem. 270, 5872-5876.
3. Balbín, M., Fueyo, A., Knäuper, V., López, J. M., Alvarez, J., Sánchez, L. M., Quesada, V., Bordallo, J., Murphy, G. and López-Otín, C. (2001). Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J. Biol. Chem. 276, 10253-10262.
4. Balbín, M., Fueyo, A., Tester, A. M., Pendás, A. M., Pitiot, A. S., Astudillo, A., Overall, C. M., Shapiro, S. D. and López-Otín, C. (2003). Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 35, 252-257.
5. Benyon, R. C., Hovell, C. J., Da Gaça, M., Jones, E. H., Iredale, J. P. and Arthur, M. J. (1999). Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 30, 977-986.
6. Betsuyaku, T., Fukuda, Y., Parks, W. C., Shipley, J. M. and Senior, R. M. (2000). Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am. J. Pathol. 157, 525-535.
7. Cabrera, S., Gaxiola, M., Arreola, J. L., Ramírez, R., Jara, P., D'Armiento, J., Richards, T., Selman, M. and Pardo, A. (2007). Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int. J. Biochem. Cell Biol. 39, 2324-2338.
8. Carew, R. M., Wang, B. and Kantharidis, P. (2012). The role of EMT in renal fibrosis. Cell Tissue Res. 347, 103-116.
9. Chen, P. and Parks, W. C. (2009). Role of matrix metalloproteinases in epithelial migration. J. Cell. Biochem. 108, 1233-1243.
10. Chen, P., McGuire, J. K., Hackman, R. C., Kim, K. H., Black, R. A., Poindexter, K., Yan, W., Liu, P., Chen, A. J., Parks, W. C. et al. (2008). Tissue inhibitor of metalloproteinase-1 moderates airway re-epithelialization by regulating matrilysin activity. Am. J. Pathol. 172, 1256-1270.
11. Chen, P., Abacherli, L. E., Nadler, S. T., Wang, Y., Li, Q. and Parks, W. C. (2009). MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting alpha(2)beta(1) integrin activation. PLoS ONE 4, e6565.
12. Chevalier, R. L. (2006). Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat. Clin. Pract. Nephrol. 2, 157-168.
13. Chiaramonte, M. G., Cheever, A. W., Malley, J. D., Donaldson, D. D. and Wynn, T. A. (2001). Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 34, 273-282.
14. Chow, F. Y., Nikolic-Paterson, D. J., Atkins, R. C. and Tesch, G. H. (2004). Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol. Dial. Transplant. 19, 2987-2996.
15. Chu, A. S., Diaz, R., Hui, J. J., Yanger, K., Zong, Y., Alpini, G., Stanger, B. Z. and Wells, R. G. (2011). Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 53, 1685-1695.
16. Conway, B. and Hughes, J. (2012). Cellular orchestrators of renal fibrosis. QJM 105, 611-615.
17. Corry, D. B., Kiss, A., Song, L. Z., Song, L., Xu, J., Lee, S. H., Werb, Z. and Kheradmand, F. (2004). Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J. 18, 995-997.
18. Craig, V. J., Quintero, P. A., Fyfe, S. E., Patel, A. S., Knolle, M. D., Kobzik, L. and Owen, C. A. (2013). Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury. J. Immunol. 190, 4283-4296.
19. Datta, A., Scotton, C. J. and Chambers, R. C. (2011). Novel therapeutic approaches for pulmonary fibrosis. Br. J. Pharmacol. 163, 141-172.
20. Degryse, A. L., Tanjore, H., Xu, X. C., Polosukhin, V. V., Jones, B. R., McMahon, F. B., Gleaves, L. A., Blackwell, T. S. and Lawson, W. E. (2010). Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am. J. Physiol. 299, L442-L452.
21. Duffield, J. S., Park, K. M., Hsiao, L. L., Kelley, V. R., Scadden, D. T., Ichimura, T. and Bonventre, J. V. (2005). Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J. Clin. Invest. 115, 1743-1755.
22. Duffield, J. S., Lupher, M., Thannickal, V. J. and Wynn, T. A. (2013). Host responses in tissue repair and fibrosis. Annu. Rev. Pathol. 8, 241-276.
23. Dunsmore, S. E., Saarialho-Kere, U. K., Roby, J. D., Wilson, C. L., Matrisian, L. M., Welgus, H. G. and Parks, W. C. (1998). Matrilysin expression and function in airwayepithelium. J. Clin. Invest. 102, 1321-1331.
24. Eddy, A. A., Kim, H., López-Guisa, J., Oda, T. and Soloway, P. D. (2000). Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int. 58, 618-628.
25. Egeblad, M. and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
26. Endo, H., Niioka, M., Sugioka, Y., Itoh, J., Kameyama, K., Okazaki, I., Ala-Aho, R., Kähäri, V. M. and Watanabe, T. (2011). Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats. Pathobiology 78, 239-252.
27. England, K. A., Price, A. P., Tram, K. V., Shapiro, S. D., Blazar, B. R. and Panoskaltsis-Mortari, A. (2011). Evidence for early fibrosis and increased airway resistance in bone marrow transplant recipient mice deficient in MMP12. Am. J. Physiol. 301, L519-L526.
28. Fallowfield, J. A., Mizuno, M., Kendall, T. J., Constandinou, C. M., Benyon, R. C., Duffield, J. S. and Iredale, J. P. (2007). Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 178, 5288-5295.
29. Flechsig, P., Hartenstein, B., Teurich, S., Dadrich, M., Hauser, K., Abdollahi, A., Gröne, H. J., Angel, P. and Huber, P. E. (2010). Loss of matrix metalloproteinase- 13 attenuates murine radiation-induced pulmonary fibrosis. Int. J. Radiat. Oncol. Biol. Phys. 77, 582-590.
30. Foronjy, R. F., Sun, J., Lemaitre, V. and D'Armiento, J. M. (2008). Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model. Hypertens. Res. 31, 725-735.
31. Garbacki, N., Di Valentin, E., Piette, J., Cataldo, D., Crahay, C. and Colige, A. (2009). Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm. Pharmacol. Ther. 22, 267-278.
32. García-Prieto, E., González-López, A., Cabrera, S., Astudillo, A., Gutiérrez- Fernández, A., Fanjul-Fernandez, M., Batalla-Solís, E., Puente, X. S., Fueyo, A., López-Otín, C. et al. (2010). Resistance to bleomycin-induced lung fibrosis in MMP- 8 deficient mice is mediated by interleukin-10. PLoS ONE 5, e13242.
33. Gill, S. E. and Parks, W. C. (2008). Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 40, 1334-1347.
34. Gill, S. E., Huizar, I., Bench, E. M., Sussman, S. W., Wang, Y., Khokha, R. and Parks, W. C. (2010a). Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am. J. Pathol. 176, 64-73.
35. Gill, S. E., Kassim, S. Y., Birkland, T. P. and Parks, W. C. (2010b). Mouse models of MMP and TIMP function. Methods Mol. Biol. 622, 31-52.
36. Gough, P. J., Gomez, I. G., Wille, P. T. and Raines, E. W. (2006). Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 116, 59-69.
37. Greenlee, K. J., Corry, D. B., Engler, D. A., Matsunami, R. K., Tessier, P., Cook, R. G., Werb, Z. and Kheradmand, F. (2006). Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J. Immunol. 177, 7312-7321.
38. Hadler-Olsen, E., Fadnes, B., Sylte, I., Uhlin-Hansen, L. and Winberg, J. O. (2011). Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 278, 28-45.
39. Hernandez-Barrantes, S., Toth, M., Bernardo, M. M., Yurkova, M., Gervasi, D. C., Raz, Y., Sang, Q. A. and Fridman, R. (2000). Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem. 275, 12080-12089.
40. Hu, Y. B., Li, D. G. and Lu, H. M. (2007). Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J. Gene Med. 9, 217-229.
41. Hu, J. H., Du, L., Chu, T., Otsuka, G., Dronadula, N., Jaffe, M., Gill, S. E., Parks, W. C. and Dichek, D. A. (2010). Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice. Circulation 121, 1637-1644.
42. Huang, S. K., White, E. S., Wettlaufer, S. H., Grifka, H., Hogaboam, C. M., Thannickal, V. J., Horowitz, J. C. and Peters-Golden, M. (2009). Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J. 23, 4317-4326.
43. Hung, C., Linn, G., Chow, Y. H., Kobayashi, A., Mittelsteadt, K., Altemeier, W. A., Gharib, S. A., Schnapp, L. M. and Duffield, J. S. (2013). Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 188, 820-830.
44. Iimuro, Y. and Brenner, D. A. (2008). Matrix metalloproteinase gene delivery for liver fibrosis. Pharm. Res. 25, 249-258.
45. Iimuro, Y., Nishio, T., Morimoto, T., Nitta, T., Stefanovic, B., Choi, S. K., Brenner, D. A. and Yamaoka, Y. (2003). Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124, 445-458.
46. Iwano, M., Plieth, D., Danoff, T. M., Xue, C., Okada, H. and Neilson, E. G. (2002). Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341-350.
47. Jirouskova, M., Zbodakova, O., Gregor, M., Chalupsky, K., Sarnova, L., Hajduch, M., Ehrmann, J., Jirkovska, M. and Sedlacek, R. (2012). Hepatoprotective effect of MMP-19 deficiency in a mouse model of chronic liver fibrosis. PLoS ONE 7, e46271.
48. Kaar, J. L., Li, Y., Blair, H. C., Asche, G., Koepsel, R. R., Huard, J. and Russell, A. J. (2008). Matrix metalloproteinase-1 treatment of muscle fibrosis. Acta Biomater. 4, 1411-1420.
49. Kang, H. R., Cho, S. J., Lee, C. G., Homer, R. J. and Elias, J. A. (2007). Transforming growth factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12. J. Biol. Chem. 282, 7723-7732.
50. Kassiri, Z., Oudit, G. Y., Kandalam, V., Awad, A., Wang, X., Ziou, X., Maeda, N., Herzenberg, A. M. and Scholey, J. W. (2009). Loss of TIMP3 enhances interstitial nephritis and fibrosis. J. Am. Soc. Nephrol. 20, 1223-1235.
51. Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J. and Wynn, T. A. (2004). IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J. Immunol. 173, 4020-4029.
52. Kawamoto, H., Yasuda, O., Suzuki, T., Ozaki, T., Yotsui, T., Higuchi, M., Rakugi, H., Fukuo, K., Ogihara, T. and Maeda, N. (2006). Tissue inhibitor of metalloproteinase- 3 plays important roles in the kidney following unilateral ureteral obstruction. Hypertens. Res. 29, 285-294
53. Kim, H., Oda, T., López-Guisa, J., Wing, D., Edwards, D. R., Soloway, P. D. and Eddy, A. A. (2001). TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 12, 736-748.
54. Kim, K. H., Burkhart, K., Chen, P., Frevert, C. W., Randolph-Habecker, J., Hackman, R. C., Soloway, P. D. and Madtes, D. K. (2005). Tissue inhibitor of metalloproteinase-1 deficiency amplifies acute lung injury in bleomycin-exposed mice. Am. J. Respir. Cell Mol. Biol. 33, 271-279.
55. Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D. and Chapman, H. A. (2006). Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. USA 103, 13180-13185.
56. Kim, E. J., Cho, H. J., Park, D., Kim, J. Y., Kim, Y. B., Park, T. G., Shim, C. K. and Oh, Y. K. (2011). Antifibrotic effect of MMP13-encoding plasmid DNA delivered using polyethylenimine shielded with hyaluronic acid. Mol. Ther. 19, 355-361.
57. Kisseleva, T. and Brenner, D. A. (2007). Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J. Gastroenterol. Hepatol. 22 Suppl., S73-S78.
58. Kolodsick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J. and Moore, B. B. (2003). Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. 29, 537-544.
59. Kriz, W., Kaissling, B. and Le Hir, M. (2011). Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J. Clin. Invest. 121, 468-474.
60. Lanone, S., Zheng, T., Zhu, Z., Liu, W., Lee, C. G., Ma, B., Chen, Q., Homer, R. J., Wang, J., Rabach, L. A. et al. (2002). Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J. Clin. Invest. 110, 463-474.
61. LeBleu, V. S., Taduri, G., O'Connell, J., Teng, Y., Cooke, V. G., Woda, C., Sugimoto, H. and Kalluri, R. (2013). Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1053.
62. Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q. et al. (2001). Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J. Exp. Med. 194, 809-821.
63. Leeming, D., He, Y., Veidal, S., Nguyen, Q., Larsen, D., Koizumi, M., Segovia-Silvestre, T., Zhang, C., Zheng, Q., Sun, S. et al. (2011). A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16, 616-628.
64. Li, Q., Park, P. W., Wilson, C. L. and Parks, W. C. (2002). Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635-646.
65. Lin, S. L., Kisseleva, T., Brenner, D. A. and Duffield, J. S. (2008). Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617-1627.
66. Liu, Y. (2010). New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 21, 212-222.
67. Liu, Y. (2011). Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 7, 684-696.
68. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y. et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128.
69. Madala, S. K., Pesce, J. T., Ramalingam, T. R., Wilson, M. S., Minnicozzi, S., Cheever, A. W., Thompson, R. W., Mentink-Kane, M. M. and Wynn, T. A. (2010). Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J. Immunol. 184, 3955-3963.
70. Manicone, A. M. and McGuire, J. K. (2008). Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol. 19, 34-41.
71. Manicone, A. M., Huizar, I. and McGuire, J. K. (2009). Matrilysin (Matrix Metalloproteinase-7) regulates anti-inflammatory and antifibrotic pulmonary dendritic cells that express CD103 (alpha(E)beta(7)-integrin). Am. J. Pathol. 175, 2319-2331.
72. Manoury, B., Nenan, S., Guenon, I., Boichot, E., Planquois, J. M., Bertrand, C. P. and Lagente, V. (2006). Macrophage metalloelastase (MMP-12) deficiency does not alter bleomycin-induced pulmonary fibrosis in mice. J. Inflamm. (Lond) 3, 2.
73. Matute-Bello, G., Wurfel, M. M., Lee, J. S., Park, D. R., Frevert, C. W., Madtes, D. K., Shapiro, S. D. and Martin, T. R. (2007). Essential role of MMP-12 in Fasinduced lung fibrosis. Am. J. Respir. Cell Mol. Biol. 37, 210-221.
74. McCawley, L. J. and Matrisian, L. M. (2001). Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534-540.
75. McGuire, J. K., Li, Q. and Parks, W. C. (2003). Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am. J. Pathol. 162, 1831-1843.
76. McQuibban, G. A., Gong, J. H., Tam, E. M., McCulloch, C. A., Clark-Lewis, I. and Overall, C. M. (2000). Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202-1206.
77. McQuibban, G. A., Butler, G. S., Gong, J. H., Bendall, L., Power, C., Clark-Lewis, I. and Overall, C. M. (2001). Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503-43508.
78. McQuibban, G. A., Gong, J. H., Wong, J. P., Wallace, J. L., Clark-Lewis, I. and Overall, C. M. (2002). Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100, 1160-1167.
79. Menghini, R., Menini, S., Amoruso, R., Fiorentino, L., Casagrande, V., Marzano, V., Tornei, F., Bertucci, P., Iacobini, C., Serino, M. et al. (2009). Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136, 663-672.e4.
80. Mouratis, M. A. and Aidinis, V. (2011). Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 17, 355-361.
81. Murphy, G. and Nagase, H. (2011). Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J. 278, 2-15.
82. Murthy, S., Ryan, A., He, C., Mallampalli, R. K. and Carter, A. B. (2010). Rac1- mediated mitochondrial H2O2 generation regulates MMP-9 gene expression in macrophages via inhibition of SP-1 and AP-1. J. Biol. Chem. 285, 25062-25073.
83. Onozuka, I., Kakinuma, S., Kamiya, A., Miyoshi, M., Sakamoto, N., Kiyohashi, K., Watanabe, T., Funaoka, Y., Ueyama, M., Nakagawa, M. et al. (2011). Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem. Biophys. Res. Commun. 406, 134-140.
84. Parks, W. C., Wilson, C. L. and López-Boado, Y. S. (2004). Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617-629.
85. Ra, H. J. and Parks, W. C. (2007). Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596.
86. Radbill, B. D., Gupta, R., Ramirez, M. C., DiFeo, A., Martignetti, J. A., Alvarez, C. E., Friedman, S. L., Narla, G., Vrabie, R., Bowles, R. et al. (2011). Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. Dig. Dis. Sci. 56, 406-416.
87. Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z. and Oster, G. (2006). Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174, 810-816.
88. Rock, J. R., Barkauskas, C. E., Cronce, M. J., Xue, Y., Harris, J. R., Liang, J., Noble, P. W. and Hogan, B. L. (2011). Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. USA 108, E1475-E1483.
89. Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E.,Lindell, K. O., Cisneros, J., Macdonald, S. D., Pardo, A. et al. (2008). MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 5, e93.
90. Rowe, R. G., Lin, Y., Shimizu-Hirota, R., Hanada, S., Neilson, E. G., Greenson, J. K. and Weiss, S. J. (2011). Hepatocyte-derived Snail1 propagates liver fibrosis progression. Mol. Cell. Biol. 31, 2392-2403.
91. Sela-Passwell, N., Rosenblum, G., Shoham, T. and Sagi, I. (2010). Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? Biochim. Biophys. Acta 1803, 29-38.
92. Seltzre, J. L. and Eisen, A. Z. (1999). Native type I collagen is not a substrate for MMP2 (gelatinase A). J. Invest. Dermatol. 112, 993-994.
93. Sen, A. I., Shiomi, T., Okada, Y. and D'Armiento, J. M. (2010). Deficiency of matrix metalloproteinase-13 increases inflammation after acute lung injury. Exp. Lung Res. 36, 615-624.
94. Siller-López, F., Sandoval, A., Salgado, S., Salazar, A., Bueno, M., Garcia, J., Vera, J., Gálvez, J., Hernández, I., Ramos, M. et al. (2004). Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 126, 1122-1133, discussion 949.
95. Sun, L., Louie, M. C., Vannella, K. M., Wilke, C. A., LeVine, A. M., Moore, B. B. and Shanley, T. P. (2011). New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am. J. Physiol. 300, L341-L353.
96. Takamiya, Y., Fukami, K., Yamagishi, S., Kaida, Y., Nakayama, Y., Obara, N., Iwatani, R., Ando, R., Koike, K., Matsui, T. et al. (2013). Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol. Dial. Transplant. 28, 55-62.
97. Tam, E. M., Moore, T. R., Butler, G. S. and Overall, C. M. (2004). Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin c domains and the MMP-2 fibronectin type II modules in collagen triple helicase activities. J. Biol. Chem. 279, 43336-43344.
98. Tocchi, A. and Parks, W. C. (2013). Functional interactions between matrix metalloproteinases and glycosaminoglycans. FEBS J. 280, 2332-2341.
99. Uchinami, H., Seki, E., Brenner, D. A. and D'Armiento, J. (2006). Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44, 420-429.
100. Vaillant, B., Chiaramonte, M. G., Cheever, A. W., Soloway, P. D. and Wynn, T. A. (2001). Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J. Immunol. 167, 7017-7026.
101. Van den Steen, P. E., Proost, P., Wuyts, A., Van Damme, J. and Opdenakker, G. (2000). Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96, 2673-2681.
102. Van den Steen, P. E., Wuyts, A., Husson, S. J., Proost, P., Van Damme, J. and Opdenakker, G. (2003). Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur. J. Biochem. 270, 3739-3749.
103. Van Lint, P. and Libert, C. (2007). Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 82, 1375-1381.
104. Veidal, S. S., Karsdal, M. A., Vassiliadis, E., Nawrocki, A., Larsen, M. R., Nguyen, Q. H., Hägglund, P., Luo, Y., Zheng, Q., Vainer, B. et al. (2011). MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS ONE 6, e24753.
105. Wang, X., Zhou, Y., Tan, R., Xiong, M., He, W., Fang, L., Wen, P., Jiang, L. and Yang, J. (2010). Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy. Am. J. Physiol. 299, F973-F982.
106. Wang, H., Lafdil, F., Wang, L., Yin, S., Feng, D. and Gao, B. (2011). Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci 1, 14.
107. White, E. S., Atrasz, R. G., Dickie, E. G., Aronoff, D. M., Stambolic, V., Mak, T. W., Moore, B. B. and Peters-Golden, M. (2005). Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am. J. Respir. Cell Mol. Biol. 32, 135-141.
108. Wynn, T. A. (2004). Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4, 583-594.
109. Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210.
110. Wynn, T. A. (2011). Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208, 1339-1350.
111. Wynn, T. A. and Ramalingam, T. R. (2012). Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028-1040.
112. Yamashita, C. M., Dolgonos, L., Zemans, R. L., Young, S. K., Robertson, J., Briones, N., Suzuki, T., Campbell, M. N., Gauldie, J., Radisky, D. C. et al. (2011). Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am. J. Pathol. 179, 1733-1745.
113. Yoshiji, H., Kuriyama, S., Miyamoto, Y., Thorgeirsson, U. P., Gomez, D. E., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Tsujinoue, H. et al. (2000). Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32, 1248-1254.
114. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., Yanase, K., Namisaki, T., Imazu, H. et al. (2002). Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36, 850-860.
115. Yu, Q. and Stamenkovic, I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163-176.
116. Yu, G., Kovkarova-Naumovski, E., Jara, P., Parwani, A., Kass, D., Ruiz, V., Lopez- Otín, C., Rosas, I. O., Gibson, K. F., Cabrera, S. et al. (2012). Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans. Am. J. Respir. Crit. Care Med. 186, 752-762.
117. Zuo, F., Kaminski, N., Eugui, E., Allard, J., Yakhini, Z., Ben-Dor, A., Lollini, L., Morris, D., Kim, Y., DeLustro, B. et al. (2002). Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. USA 99, 6292-6297.